Kennedy Jr. will divest his interests in several biopharma companies, including CRISPR Therapeutics and Dragonfly Therapeutics, if confirmed by the ...
Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...
CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...
CRISPR-Cas9 is one of the biggest discoveries of the 21st century. Since it was developed in 2012, this gene-editing tool has revolutionized biology research, making it easier to study disease and ...
ZUG, Switzerland and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback